A new class of oral drugs designed to treat breast cancer is generally well tolerated, according to new research. The drugs,known as cyclin-dependent kinase (CDK) inhibitors, also have a manageable toxicity profile for most patients. Those conclusions came after a comprehensive review of toxicities and drug interactions related to CDK. The research was published in… Continue reading Side Effects Not a Problem for a New Class of Breast Cancer Drugs